Jenner Institute, University of Oxford, Oxford, UK.
Philos Trans R Soc Lond B Biol Sci. 2011 Oct 12;366(1579):2841-9. doi: 10.1098/rstb.2011.0100.
The Royal Society convened a meeting on the 17th and 18th November 2010 to review the current ways in which vaccines are developed and deployed, and to make recommendations as to how each of these processes might be accelerated. The meeting brought together academics, industry representatives, research sponsors, regulators, government advisors and representatives of international public health agencies from a broad geographical background. Discussions were held under Chatham House rules. High-throughput screening of new vaccine antigens and candidates was seen as a driving force for vaccine discovery. Multi-stakeholder, small-scale manufacturing facilities capable of rapid production of clinical grade vaccines are currently too few and need to be expanded. In both the human and veterinary areas, there is a need for tiered regulatory standards, differentially tailored for experimental and commercial vaccines, to allow accelerated vaccine efficacy testing. Improved cross-fertilization of knowledge between industry and academia, and between human and veterinary vaccine developers, could lead to more rapid application of promising approaches and technologies to new product development. Identification of best-practices and development of checklists for product development plans and implementation programmes were seen as low-cost opportunities to shorten the timeline for vaccine progression from the laboratory bench to the people who need it.
英国皇家学会于 2010 年 11 月 17 日至 18 日召开会议，审议当前疫苗开发和应用的方式，并就如何加快这些流程提出建议。会议聚集了来自广泛地理背景的学术界人士、行业代表、研究赞助商、监管机构、政府顾问和国际公共卫生机构代表。讨论是在“查塔姆宫规则”下进行的。高通量筛选新的疫苗抗原和候选物被视为疫苗发现的驱动力。目前，能够快速生产临床级疫苗的多方利益相关者、小规模制造设施太少，需要扩大。在人类和兽医领域，需要针对实验性和商业疫苗制定分层监管标准，以允许加速疫苗功效测试。在行业和学术界之间，以及在人类和兽医疫苗开发人员之间，加强知识交叉授粉，可能会导致更迅速地将有前途的方法和技术应用于新产品开发。确定最佳实践，并为产品开发计划和实施计划制定清单，被视为缩短疫苗从实验室走向有需要的人群的时间线的低成本机会。
